Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT02592980

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02592980
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02592980. Randomized; single masking; primary purpose treatment. Start 2016-01 (actual); primary completion 2019-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients
Intervention (Genetic)
Pharmacogenetic anticoagulation
Intervention (Drug)
Traditional anticoagulation
Lead sponsor
University of Sao Paulo General Hospital (class: other)
Collaborator
InCor Heart Institute (class: other)
Collaborator
Farmoquimica S.A. (class: industry)
Collaborator
University of Sao Paulo (class: other)

Record details

Record id
cardio:ct-nct02592980
Content hash
884bcfbcb0ed885468a177e68808df02b1986b4f8621247937fd62f15702a311